Vanda Pharmaceuticals (VNDA) Cash from Operations (2010 - 2026)

Vanda Pharmaceuticals has reported Cash from Operations for 17 years, with the latest figure at 50218000.0 in Q1 2026.

• Quarterly Cash from Operations fell 51.5% year-over-year to 50218000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 126513000.0 (down 124.02% YoY) and the FY2025 annual result came in at 109442000.0, down 594.56% from the prior year.
• Cash from Operations retreated to 50218000.0 in Q1 2026 per VNDA's latest filing, from 29417000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 31803000.0 in Q1 2023 and troughed at 50218000.0 in Q1 2026.
• A 5-year average of 7684235.29 and a median of 3732000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2023 and 2025: Cash from Operations surged 686.04% in 2023, then tumbled 1518.99% in 2025.
• Over 5 years, Cash from Operations stood at 9416000.0 in 2022, then slumped by 139.63% to 3732000.0 in 2023, then jumped by 51.31% to 1817000.0 in 2024, then sank by 1518.99% to 29417000.0 in 2025, then plunged by 70.71% to 50218000.0 in 2026.
• According to Business Quant data, Cash from Operations over the past three periods registered 50218000.0, 29417000.0, and 31626000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.